BioAscent has experienced continued growth in demand for its in silico discovery services. Despite the challenging market conditions in 2023, the company recently reported promising growth in the wake of sustained demand for its services, with in silico discovery experiencing a 27% growth in revenue.

The in silico discovery team was launched in 2021, to strengthen BioAscent’s integrated drug discovery service to clients ranging from small, virtual biotechs through to larger, well-established pharma companies across the globe. Since then, the team has grown to support customer demand, broadening its capabilities.

Commenting on the growth, Associate Director and Head of In Silico Discovery, Angelo Pugliese, says:

“This continued drive in demand for our expertise has been encouraging to see. Increasingly our customers are recognising the value computational chemistry can bring to drug discovery projects. Our computational chemists work closely with the scientists in medicinal chemistry, biosciences and compound management to help customers make better decisions, accelerate timelines, reduce cost, and ultimately improve the likelihood of success.

“The market trends are clear, with a growing interest in using AI and machine learning to enhance drug discovery. Our computational chemists are experienced in applying cutting-edge in silico methodologies to drug design and discovery, and are progressive in the way they work, embracing new trends and technologies as required by customer projects.”

To find out more about in silico discovery services at BioAscent, click here.